This brand name is authorized in Turkey.
The drug TRATEZ contains a combination of these active pharmaceutical ingredients (APIs):
1
|
UNII
48A5M73Z4Q - ATORVASTATIN CALCIUM TRIHYDRATE
|
|
Atorvastatin is a selective, competitive inhibitor of HMG-CoA reductase. Atorvastatin lowers plasma cholesterol and lipoprotein serum concentrations by inhibiting HMG-CoA reductase and subsequently cholesterol biosynthesis in the liver and increases the number of hepatic LDL receptors on the cell surface for enhanced uptake and catabolism of LDL. |
|
2
|
UNII
EOR26LQQ24 - EZETIMIBE
|
|
Ezetimibe is in a new class of lipid-lowering compounds that selectively inhibit the intestinal absorption of cholesterol. The molecular target of ezetimibe is the sterol transporter, Niemann-Pick C1-Like 1 (NPC1L1), which is responsible for the intestinal uptake of cholesterol. |
|
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC Group | Classification | |
|---|---|---|
| C10BA05 | C Cardiovascular system → C10 Lipid modifying agents → C10B Lipid modifying agents, combinations → C10BA Combinations of various lipid modifying agents | |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| TR | İlaç ve Tıbbi Cihaz Kurumu | 8699580010336 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.